Elucidating the precise pharmacological mechanism of motion (MOA) of naturally developing compounds may be demanding. Although Tarselli et al. (60) formulated the first de novo artificial pathway to conolidine and showcased this naturally happening compound successfully suppresses responses to both equally chemically induced and inflammation-derive